November 19, 2012
There is a new name in the very lucrative surgical robotics space -- Titan -- and it wants a piece of Intuitive Surgical's (Nasdaq: ISRG ) market. Titan's business model will be very familiar for anyone who knows Intuitive Surgical: Sell a robotic surgery platform to health care facilities, and then design and sell tools for that robot designed to perform specific procedures. It has even named its robot Amadeus, paying tribute to Mozart in the way that Intuitive's da Vinci robot is a nod to Leonardo da Vinci. So if Titan can beat Intuitive's prices, should investors be worried? In this video, Motley Fool analyst Brenton Flynn tells us how these fears are a long way off and a lot needs to happen first. But, he warns, keep an eye on Titan, just in case.
A true renegade in the health care industry, Intuitive Surgical rebelled against the status quo to lead a revolution in medical robotics. Early investors experienced unimaginable gains, some making as much as 30 times their initial investment. Even with those enormous gains in the rearview mirror, the stock could have plenty of room to run into the future. In a brand new premium report on Intuitive Surgical, we've commissioned Karl Thiel to outline the company's key opportunities and risks with surgical precision. As one of the minds behind our Rule Breakers recommendation of the stock in 2005 (before it went on to gain more than 1,000%) Thiel knows the Intuitive Surgical story inside and out. It's a must-read for any current or prospective investor, and comes loaded with a full year of analyst updates. Make sure to claim your copy today by clicking here now.